| Literature DB >> 32472403 |
Luca Aldrighetti1, Ugo Boggi2, Massimo Falconi3, Felice Giuliante4, Federica Cipriani5, Francesca Ratti5, Guido Torzilli6.
Abstract
The safety of minimally invasive procedures during COVID pandemic remains hotly debated, especially in a country, like Italy, where minimally invasive techniques have progressively and pervasively entered clinical practice, in both the hepatobiliary and pancreatic community. A nationwide snapshot of the management of HPB minimally invasive surgery activity during COVID-19 pandemic is provided: a survey was developed and conducted within AICEP (Italian Association of HepatoBilioPancreatic Surgeons) with the final aim of conveying the experience, knowledge, and opinions into a unitary report enabling more efficient crisis management. Results from the survey (81 respondents) show that, in Italian hospitals, minimally invasive surgery maintains its role despite the COVID-19 pandemic, with the registered reduction of cases being proportional to the overall reduction of the HPB surgical activity. Respondents agree that the switch from minimally invasive to open technique can be considered as a valid option for cases with a high technical complexity. Several issues merit specific attention: screening for virus positivity should be universally performed; only expert surgical teams should operate on positive patients and specific technical measures to lower the biological risk of contamination during surgery must be followed. Future studies specifically designed to establish the true risks in minimally invasive surgery are suggested. Furthermore, a standard and univocal process of prioritization of patients from Regional Healthcare Systems is advisable.Entities:
Keywords: COVID-19; Liver; Minimally invasive; Pancreas; Pandemic
Mesh:
Year: 2020 PMID: 32472403 PMCID: PMC7259429 DOI: 10.1007/s13304-020-00815-5
Source DB: PubMed Journal: Updates Surg ISSN: 2038-131X
HPB activity during the COVID-19 pandemic
| Hub centers for COVID-19 | 67/81 (82.7%) |
| Activity | |
| Hepatobiliary | 68/81 (84%) |
| Pancreatic | 55/81 (67.9%) |
| Reduction of activity | |
| No reduction | 8/81 (9.9%) |
| < 50% | 14/81(17.3%) |
| ≥ 50% | 59/81 (25.9%) |
| Reduction of MIS liver activity | |
| No reduction | 11/68 (16.2%) |
| 25% | 12/68 (17.6) |
| ≥ 50% | 45/68 (66.2) |
| Reduction of MIS pancreatic activity | |
| No reduction | 3/55 (5.5%) |
| 25% | 10/55 (18.2%) |
| ≥ 50% | 42/55 (76.4) |
| Reduction of robotic activity | |
| No reduction | 4/28 (14.3) |
| 25% | 4/28 (14.3) |
| ≥ 50% | 20/28 (71.4%) |
| Hospital status | |
| Usual activity | 6/81 (7.4%) |
| No elective benign surgery | 56/81 (69.1%) |
| No any elective surgery | 15 (18.5%) |
| Complete lockdown | 4 (4.9%) |
Minimally invasive HPB surgery during the COVID-19 pandemic
| Liver | |
| MIS liver activity as a priority for referral to hub | 52/76 (68.4%) |
| MIS pancreas activity as a priority for referral to hub | 46/76 (60.5%) |
| Low complexity liver resection: switch MIS/open at hub center | |
| Strongly agree or agree | 30/76 (39.5%) |
| Disagree or strongly disagree | 46/76 (60.5%) |
| Intermediate complexity liver resection: switch MIS/open at hub center | |
| Strongly agree or agree | 40/75 (53.3%) |
| Disagree or strongly disagree | 35/75 (46.7%) |
| High complexity liver resection: switch MIS/open at hub center | |
| Strongly agree or agree | 61/76 (80.3%) |
| Disagree or strongly disagree | 15/76 (19.7%) |
| Pancreas | |
| Left pancreatectomy: switch MIS/open at hub center | |
| Strongly agree | 37/76 (48.7%) |
| Disagree | 39/76 (51.3%) |
| Whipple procedure: switch MIS/open at hub center | |
| Strongly agree | 64/75 (85.3%) |
| Disagree | 11/75 (14.7%) |
| General | |
| Prioritization of patients based on: | |
| Time from entry in the waiting list | 28/81 (34.6%) |
| Local resectability pattern | 39/81 (48.1%) |
| Biological aggressiveness | 60/81 (74.1%) |
| Alternative or bridging (including neoadjuvant chemo) treatments available or not | 50/81 (61.7%) |
| ASA score or Charlson Comorbidity Index | 23/81 (28.4) |
| General performance status | 20/81 (24.7%) |
| Indication to MIS in SARS-CoV2 patients | |
| Unmodified as per the timing and type of surgery required | 7/80 (8.8%) |
| Unmodified as per the timing and type of surgery required just if asymptomatic | 7/80 (8.8%) |
| Delayed in timing until SARS-CoV-2 negativization was proved | 66/80 (82.5%) |
| Technical variations in MIS | |
| No | 19/74 (25.7%) |
| Yes: specific smoke aspirations | 36/74 (48.6%) |
| Yes: specific CO2 insufflations | 11/74 (14.9%) |
| Yes: specific attention to skin incisions appropriate to port dimensions | 23/74 (31.1%) |
| Yes: preference for trocars with balloon fixation | 25/74 (33.8%) |
| Yes: energy devices not used | 2/74 (2.7%) |
| Yes: pneumoperitoneal pressures kept at minimum | 28/74 (37.8%) |
| Yes: pneumoperitoneum aspiration before removal of trocars | 41/74 (55.4%) |
| Yes: minimization of time of Trendelenburg position | 6/74 (8.1%) |
| Fast-track protocol during COVID-19 | |
| Yes, same indications | 58/78 (74.4%) |
| Yes, reduced number of indications | 15/78 (19.2%) |
| No, stopped | 5/78 (6.4%) |